Results · Jul-Sep 2026 · filed 19 Oct 2026
Tatva Chintan Pharma Chem Q2 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 76% to ₹217 crore from ₹124 crore in Jul-Sep 2025.
Operating profit grew 83% to ₹40.7 crore, an operating margin of 18.7% (up 0.7 points from a year ago).
Net profit grew 116% to ₹21.5 crore from ₹9.9 crore in Jul-Sep 2025.
Against Apr-Jun 2026: sales +30%, net profit +34%.
Jul-Sep 2026 vs a year ago
| ₹ crore | Jul-Sep 2026 | Jul-Sep 2025 | Change |
|---|---|---|---|
| Sales | 217.3 | 123.5 | +76% |
| Operating profit (EBITDA) | 40.7 | 22.2 | +83% |
| Operating margin | 18.7% | 18.0% | +0.7 pts |
| Net profit | 21.5 | 9.9 | +116% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
Filings that week
- 20 Oct 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 19 Oct 2026Updated Investor Presentation
- 19 Oct 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 19 Oct 2026Intimation Regarding Cancellation Of Schedule Of Earnings Call
- 19 Oct 2026Board Meeting Outcome for Board Meeting Outcome For Outcome Of The Board Meeting Held On 19.10.2026
- 19 Oct 2026Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September2026
- 16 Oct 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.